Investigation into the use FDG PET/CT in Intensive Care patients that show no/little recovery

VIsualizing Persistent inflammation and occult infEctions in non-Recovering ICU patients with FDG PET/CT - VIsualizing Persistent inflammation and occult infEctions in non-Recovering ICU patients with FDG PET/CT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58224

Enrollment

Registered

2025-06-20

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Critical Illness, Chronic Critical Illness, PET, Critical Care Ongoing serious illness in ICU, Long-lasting critical illness, advanced body scan, Intensive hospital care

Interventions

[18F]FDG PET/CT scan and Contrast-Enhanced CT scan

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult (male/female = 50 years of age) patientsAdmission to the ICU = 7 daysOrgan failure defined as the need for invasive ventilation or the necessity of vasopressor therapy.Either inflammation/infection are parameters persistently elevated. Defined as a CRP >75 mmol/L and no persistent decrease of >50% in the past three days. OR the patient receives tacrolimus, cellcept, azathioprine (AZA), anti-thymocyte globulin (ATG), basiliximab, tocilizumab or high dose/continuous corticosteroidsPET transport deemed safe by attending clinician (staff intensivist)Informed consent signed by patient or legal representative

Exclusion criteria

Exclusion criteria: Women who are pregnant or breastfeeding.Known allergies to iodine contrast.Inability to attain informed consent.Preparatory failure defined as serum glucose >11 mmol/L before PET-scan.Too unstable for transport as judged by the treating staff intensivist.Patients suffering from isolated neurological pathology requiring ICU admission.Patients suffering from acute pancreatitis requiring ICU admission.Patients receiving extra-corporeal membrane oxygenation (ECMO).

Design outcomes

Primary

Measure	Time frame
To evaluate incidence of [18F]FDG PET/CT findings compared to contrast-enhanced CT in patients with persistent critical illness.	—

Secondary

Measure	Time frame
Secondary Objective(s): To evaluate the incidence of therapy change following [18F]FDG PET/CT.To explore the relationship between [18F]FDG PET/CT findings and circulating biomarkers.Tertiary Objective(s):To estimate the effect of imaging on ICU LOS, ICU- and hospital mortality and the length of required organ support using a retrospective matched cohort from 2023-2024.	—

Countries

Belgium, Netherlands

Contacts

Public ContactC.P. Stee

Universitair Medisch Centrum Groningen

c.p.van.stee@umcg.nl050 3615617

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026